DE4021083A1 - Phospholipid formulations for medicinal and cosmetic baths - contg. phosphatidyl choline, oil component e.g. wax ester, alcohol, stabiliser, active ingredient and opt. auxiliaries - Google Patents
Phospholipid formulations for medicinal and cosmetic baths - contg. phosphatidyl choline, oil component e.g. wax ester, alcohol, stabiliser, active ingredient and opt. auxiliariesInfo
- Publication number
- DE4021083A1 DE4021083A1 DE19904021083 DE4021083A DE4021083A1 DE 4021083 A1 DE4021083 A1 DE 4021083A1 DE 19904021083 DE19904021083 DE 19904021083 DE 4021083 A DE4021083 A DE 4021083A DE 4021083 A1 DE4021083 A1 DE 4021083A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- oil
- formulations according
- phospholipid formulations
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 238000009472 formulation Methods 0.000 title claims abstract description 75
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 61
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 239000004480 active ingredient Substances 0.000 title claims abstract description 34
- 239000003381 stabilizer Substances 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 239000004164 Wax ester Substances 0.000 title claims abstract description 6
- 235000019386 wax ester Nutrition 0.000 title claims abstract description 6
- 239000003921 oil Substances 0.000 claims abstract description 79
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 5
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 4
- 229920002545 silicone oil Polymers 0.000 claims abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 2
- 239000002480 mineral oil Substances 0.000 claims abstract 2
- 235000010446 mineral oil Nutrition 0.000 claims abstract 2
- 230000007935 neutral effect Effects 0.000 claims abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 239000013543 active substance Substances 0.000 claims description 23
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000002304 perfume Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 8
- -1 dicarboxylic acid ester Chemical class 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 4
- 230000007062 hydrolysis Effects 0.000 abstract description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 65
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 23
- 239000003995 emulsifying agent Substances 0.000 description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
- 229930003427 Vitamin E Natural products 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 8
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 8
- 229940042585 tocopherol acetate Drugs 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000787 lecithin Substances 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N (Z,Z,Z)-Octadeca-9,12,15-trienoic acid Natural products CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000010775 animal oil Substances 0.000 description 4
- 239000003788 bath preparation Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000021302 avocado oil Nutrition 0.000 description 3
- 239000008163 avocado oil Substances 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 229940036350 bisabolol Drugs 0.000 description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 239000010496 thistle oil Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003913 econazole Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
- 235000019719 rose oil Nutrition 0.000 description 2
- 239000010666 rose oil Substances 0.000 description 2
- 239000010668 rosemary oil Substances 0.000 description 2
- 229940058206 rosemary oil Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VCLJODPNBNEBKW-UHFFFAOYSA-N 2,2,4,4,6,8,8-heptamethylnonane Chemical compound CC(C)(C)CC(C)CC(C)(C)CC(C)(C)C VCLJODPNBNEBKW-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- FDXIVRQIMPXJGE-UHFFFAOYSA-N 2-(2-hydroxybenzoyl)oxyethyl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OCCOC(=O)C1=CC=CC=C1O FDXIVRQIMPXJGE-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- LYYQNGYNNOQPPY-UHFFFAOYSA-N 2-hydroxybenzoic acid;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.OC(=O)C1=CC=CC=C1O LYYQNGYNNOQPPY-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SJIDAAGFCNIAJP-UHFFFAOYSA-N 6-methylheptyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCC(C)C SJIDAAGFCNIAJP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000004758 Bergkiefer Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000010450 Pino mugo Nutrition 0.000 description 1
- 241001136577 Pinus mugo Species 0.000 description 1
- 235000002914 Pinus uncinata Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000013709 carrot oil Nutrition 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 229940080277 cholesteryl sulfate Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229940064982 ethylnicotinate Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940106579 hops extract Drugs 0.000 description 1
- 239000001906 humulus lupulus l. absolute Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 239000001851 juniperus communis l. berry oil Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229940119169 yarrow flower extract Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Gegenstand der Erfindung sind Phospholipidformulierungen, die pharmazeutische oder kosmetische Wirkstoffe enthalten, und ihre Verwendung zur Herstellung liposomaler medizinischer oder kosmetischer Badezubereitungen.The invention relates to phospholipid formulations, the pharmaceutical or cosmetic active ingredients and their use for producing liposomal medical or cosmetic bath preparations.
Badezubereitungen, insbesondere konventionelle Ölbäder, werden in der Medizin und der Kosmetik sehr häufig angewandt, um der Haut großflächig Wirkstoffe zuzuführen. Dies kann in Form von Teilbädern, wie z. B. Fußbädern, Sitzbädern, Armbädern oder Vollbädern erfolgen. Bath preparations, in particular conventional oil baths, are very commonly used in medicine and cosmetics, in order to supply active ingredients to the skin over a large area. This can be done in the form of partial baths, such as. Footbaths, Seating baths, baths or full baths take place.
Der Begriff des Wirkstoffs ist hierbei unterschiedlich. Während ein pharmazeutischer Wirkstoff dazu geeignet ist, Hautkrankheiten zu heilen oder günstig zu beeinflussen, Erkältungskrankheiten zu lindern, auf Kreislauf und Stoffwechsel einzuwirken, hat ein kosmetischer Wirkstoff eine andere Funktion. Ein kosmetischer Wirkstoff vermindert z. B. die Austrocknung der Haut, bewirkt eine Hautglättung, macht die Haut weich, verbessert die Elastizität der Haut, schützt die Haut vor den Wirkungen der UV-Strahlung.The term of the active ingredient is different here. While a pharmaceutical agent is suitable is to heal or treat skin diseases affect relieve colds on Circulation and metabolism have a cosmetic effect Active ingredient a different function. A cosmetic Active ingredient reduces z. B. the dehydration of Skin, smoothes the skin, softens the skin, improves the elasticity of the skin, protects the skin from the effects of UV radiation.
Die wichtigsten Inhaltsstoffe eines Ölbads sind Ölkomponente, Wirkstoff sowie einer oder mehrere Emulgatoren, die eine Dispersion der Ölkomponente und des Wirkstoffs, insbesondere wenn er lipophilen Charakter hat, im Wasser ermöglichen.The most important ingredients of an oil bath are oil component, Active substance and one or more emulsifiers, a dispersion of the oil component and the Active ingredient, especially if it has lipophilic character has to allow in the water.
Typische Emulgatoren für Ölbäder sind z. B. ethoxylierte oder propoxylierte Fettalkohole, Ester der Phosphorsäure, Ricinolsäuresulfate, Alkoholethersulfate etc. Je nach Menge des Emulgatoranteils ergeben sich nach Vermischen der Formulierung mit dem Badewasser oberflächenspreitende (niedriger Anteil), milchige oder klare Bäder (hoher Anteil), d. h. die Größe der Ölpartikel der entstehenden Emulsionen wird durch die Emulgatorkonzentration beeinflußt.Typical emulsifiers for oil baths are z. B. ethoxylated or propoxylated fatty alcohols, esters of phosphoric acid, Ricinoleic acid sulfates, alcohol ether sulfates, etc. Each The amount of emulsifier content results after mixing the formulation with the bathwater surface spreading (low proportion), milky or clear baths (high proportion), d. H. the size of the oil particles The resulting emulsions are characterized by the emulsifier concentration affected.
Emulgatoren haben neben ihrem Vorteil, lipophile Stoffe in Wasser dispergieren zu können, zwangsläufig den Nachteil, auf die Haut entfettend zu wirken und somit auch sehr viel Wirkstoff, insbesondere wenn er lipophil ist, um Badewasser zu binden. Auch ist dem Fachmann wohlbekannt, daß Emulgatoren in Abhängigkeit einer ihrer Stoffkonstanten, nämlich der kritischen Micellenkonzentration, irritierend auf die Haut wirken können. Je höher die kritische Micellenkonzentration ist, umso höher ist der Anteil nicht-micellar gebundener Emulgatormoleküle und damit das Irritationspotential. Hinzu kommt, daß übliche Emulgatoren, insbesondere anionische, in der Hornschicht der Haut einen starken Quelleffekt bewirken (U. Zeidler, Ärtzliche Kosmetologie 19 (3), 208-219 (1989)). Ölbäder sind daher, insbesondere im kosmetischen Bereich, nicht unumstritten.Emulsifiers have besides their advantage, lipophilic substances to be able to disperse in water, inevitably the Disadvantage of degreasing the skin and thus also very much active ingredient, especially if he is lipophilic is to tie bath water. Also, the expert well-known that emulsifiers depending on a their substance constants, namely the critical micelle concentration, irritating to the skin. The higher the critical micelle concentration, the better higher is the proportion of non-micellar bound emulsifier molecules and thus the irritation potential. in addition comes that conventional emulsifiers, especially anionic, in the horny layer of the skin strong source effect (U. Zeidler, Ärztzliche Cosmetology 19 (3), 208-219 (1989)). Oil baths are therefore, especially in the cosmetic field, not undisputed.
Man kann daher als Ziel für eine optimale Ölbadkomposition definieren, daß die Formulierung möglichst viel Ölkomponente und Wirkstoff enthalten soll, möglichst wenig Emulgator, der wiederum möglichst wenig entfettend wirkt und außerdem ein möglichst niedriges Irritationspotential aufweisen soll, wobei die Ölkomponente und der Wirkstoff möglichst gut verfügbar sind.One can therefore aim for an optimal oil bath composition define that the wording as possible should contain much oil component and active ingredient, if possible little emulsifier, in turn, as little as possible degreasing and also the lowest possible Irritation potential should have, wherein the oil component and the active ingredient are available as well as possible.
Hier sind den üblichen Emulgatoren Grenzen gesetzt. Hinzu kommt, daß z. B. bei niedrigen Emulgatorkonzentrationen aufgrund von Aufrahmungserscheinungen der Ölkomponente unangenehme und mühsam zu entfernende Fettränder in der Badewanne entstehen.Here are the usual emulsifiers limits. In addition, that z. B. at low Emulgatorkonzentrationen due to framing phenomena of the oil component unpleasant and difficult to remove fat margins arise in the bathtub.
Auch ist der Nutzen medizinischer Ölbäder umstritten, da die Bioverfügbarkeit der Wirkstoffe, wie oben dargelegt, vom Emulgator sehr stark beeinflußt wird.Also, the benefits of medical oil baths are controversial since the bioavailability of the active substances, as explained above, is strongly influenced by the emulsifier.
Eine Verbesserung der Ölbadeigenschaften wurde dadurch erreicht, daß man eine Mischung aus Emulgator (Polyethylenglykol 400-dioleat). Isopropylpalmitat, Maisöl, Lecithin und Wasser vorgeschlagen hat (M. Singer, Clinical Medicine 71, 1921-1924 (1964)). Diese Mischung ist aber insofern auch nachteilig, als sie einen nichtionogenen Emulgator benutzt. Nichtionogene Emulgatoren sind dafür bekannt, daß sie im Vergleich zu anderen Emulgatortypen das größte Penetrationsvermögen in die Haut haben (W. Kästner, Seifen, Öle, Fette, Wachse 116 (1), 3-9 (1990)); außerdem enthält das System aufgrund seines Wassergehalts ein Konservierungsmittel (p-Hydroxybenzoesäurebutylester). Die Allergieauslösung von Konservierungsmitteln ist hinreichend bekannt, und man versucht daher gerade bei Produkten kosmetischer und medizinischer Art dieses Risiko durch die Verwendung konservierungsfreier Präparate auszuschließen; dies ist jedoch hier nicht möglich. Ein weiterer Nachteil ist die bekannte geringe Haltbarkeit von wäßrigen Lecithinprodukten, da sie durch Hydrolyse der Esterbindungen langsam Fettsäuren abspalten und sich so die Eigenschaften der Produkte verändern. Darüber hinaus ist die beschriebene Mischung nicht gegen Autoxidation geschützt. Dies ist jedoch sehr wichtig, da Lecithin durch seinen hohen Linolsäuregehalt besonders empfindlich ist. Diese Empfindlichkeit macht sich, auch für den Laien leicht feststellbar, durch ranzigen Geruch bemerkbar.An improvement of the Ölbadeigenschaften was characterized achieved that a mixture of emulsifier (polyethylene glycol 400 dioleate). Isopropyl palmitate, corn oil, Lecithin and water (M. Singer, Clinical Medicine 71, 1921-1924 (1964)). This mixture but is also disadvantageous insofar as it is a nonionic Emulsifier used. Nonionic emulsifiers are known to be compared to others Emulsifier types the greatest penetration capacity in the Have skin (W. Kästner, soaps, oils, fats, waxes 116 (1), 3-9 (1990)); In addition, the system contains due to its water content is a preservative (butyl p-hydroxybenzoate). The allergic release of Preservatives is well known, and one tries therefore especially for products cosmetic and medical nature of this risk by use to exclude preservative-free preparations; This is but not possible here. Another disadvantage is the known low durability of aqueous lecithin products, since they are due to hydrolysis of the ester bonds Slowly split off fatty acids and get the properties of the products. In addition, the described mixture is not protected against autoxidation. However, this is very important since lecithin particularly sensitive due to its high linoleic acid content is. This sensitivity makes up, too The layman easily detectable, by rancid smell noticeable.
Der Wassergehalt hat noch einen weiteren Nachteil, nämlich, daß Ölkomponente und lipophiler Wirkstoff nur einen beschränkten Gehalt haben können, zum anderen aber auch keine hydrolyseempfindlichen Wirkstoffe wie z. B. Vitamin-A-acetat (Akne-Mittel) formuliert werden können. Letzterer Wirkstoff ist außerdem auch sehr oxidationsempfindlich. Die rückfettende Wirkung von Lecithin und der Ölkomponente kann aufgrund des anwesenden Emulgators immer noch nicht voll ausgenutzt werden.The water content has another disadvantage, namely, that oil component and lipophilic active ingredient only may have a limited salary, on the other hand but also no hydrolysis-sensitive agents such as z. For example, vitamin A acetate (acne remedies) can be formulated can. The latter ingredient is also very good sensitive to oxidation. The moisturizing effect of Lecithin and the oil component may due to the present Emulsifier still not fully utilized become.
Auch Mischungen von anion- oder kationaktiver Tenside mit Lecithin wurden erwähnt (H. Rebmann, Seifen, Öle, Fette, Wachse 100 (14), 343-346 (1974)). Nachteile dieser Formulierungen sind jedoch auch hier die Anwesenheit von Emulgatoren, die dem Fachmann für ihr Irritationspotential und/oder ihren Einfluß auf die Hornschichtquellung (siehe oben) bekannt sind. Auch alle anderen Nachteile der oben genannten Mischung konnten nicht beseitigt werden, mit Ausnahme, daß Vitamin E als zuzusetzendes Antioxidans beschrieben wurde. Aber auch hier ist dem Fachmann bekannt, das Vitamin E eine nur beschränkte Wirkung als Antioxidans hat, da es selbst gegenüber Luftsauerstoff sehr empfindlich ist. Also mixtures of anionic or cationic surfactants with lecithin were mentioned (H. Rebmann, soaps, oils, Fats, Waxes 100 (14), 343-346 (1974)). disadvantage However, these formulations are also the presence here of emulsifiers that the expert for their irritation potential and / or their influence on horny layer swelling (see above) are known. All too other disadvantages of the above mixture could can not be eliminated, except that vitamin E as has been described to be added antioxidant. But also Here is the expert known, the vitamin E one only has limited effect as an antioxidant, since it itself is very sensitive to atmospheric oxygen.
Als weitere Lösung für diese Probleme wurden kürzlich liposomale (Öl-) Bäder vorgeschlagen, bei denen Liposomen als Träger für Öl- und Wirkstoffkomponente dienen (H. Lautenschläger und J. Röding, Parfümerie und Kosmetik 70 (12), 757-764)).As another solution to these problems have been recently liposomal (oil) baths suggested where liposomes serve as a carrier for oil and drug component (H. Lautenschläger and J. Röding, perfumery and cosmetics 70 (12), 757-764)).
Liposomen sind Vesikel mit unterschiedlichster Struktur. Je nach Herstellungsverfahren unterscheidet man unilamellare, oligolamellare, multilamellare oder fusionierte Körper mit Membranstruktur und einem Durchmesser von ca. 15-3500 nm. Eine Übersicht gibt H. P. Fiedler, Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, Verlag Editio Cantor, Aulendorf 1989, S. 744-746.Liposomes are vesicles with a wide variety of structures. Depending on the manufacturing process one differentiates unilamellar, oligolamellar, multilamellar or fused body with membrane structure and a diameter from approx. 15-3500 nm. An overview is given by H. P. Fiedler, Lexicon of excipients for pharmacy, cosmetics and adjacent areas, Publisher Editio Cantor, Aulendorf 1989, p. 744-746.
Liposomen im allgemeinen Sprachgebrach sind aus natürlichen, halbsynthetischen und synthetischen Phospholipiden zusammengesetzt, wobei die Hauptkomponente meist aus Phosphatidylcholin besteht. Nebenkomponenten sind z. B. Phosphatidylethanolamin, Phosphatidylinosit, Phosphatidsäure. Man unterscheidet ungesättigte (natürliche), teilhydrierte und hydrierte Phospholipide gemäß ihrer Fettsäurebesetzung.Liposomes in general speech are made of natural, semisynthetic and synthetic phospholipids composed, with the main component mostly is phosphatidylcholine. Secondary components are z. B. phosphatidylethanolamine, phosphatidylinositol, Phosphatidic. We distinguish between unsaturated (natural), partially hydrogenated and hydrogenated phospholipids according to their fatty acid occupation.
Ähnlich wie die biologischen Zellen können Liposomen in den vesikulären Innenbereich wasserlösliche Substanzen und in den Membranen amphiphile und lipophile Substanzen speichern (beladene Liposomen). Beispiele für die Beladungen in den Membranen sind Vitamin E, Retinoide, Steroide, lipophile und amphiphile Wirkstoffe, pflanzliche und tierische Öle.Similar to the biological cells, liposomes in the vesicular interior water-soluble substances and in the membranes amphiphilic and lipophilic substances store (loaded liposomes). examples for the loadings in the membranes are vitamin E, retinoids, Steroids, lipophilic and amphiphilic drugs, vegetable and animal oils.
Insbesondere lipophile Wirkstoffe, pflanzliche und tierische Öle sind im Kosmetikbereich wichtig für eine optimale Hautpflege, speziell zur Behandlung trockener Haut. Auch bei hochungesättigten Ölen, die z. B. zur Behandlung von atopischer Dermatitis eingesetzt werden (H. P. Nissen, W. Wehrmann, U. Kroll und H. W. Kreysel, Fat. Sci. Technol. 90 (7), 268-271 (1988)), ist die Verteilung und das Eindringen in die Haut von entscheidender Bedeutung. Liposomen sind daher bezüglich Verteilung und Penetration in die Haut das ideale Trägersystem.In particular, lipophilic active ingredients, plant and animal Oils are important in the cosmetics industry for one optimal skin care, especially for the treatment of dry Skin. Even with highly unsaturated oils, the z. B. for Treatment of atopic dermatitis (H.P. Nissen, W. Wehrmann, U. Kroll and H.W. Kreysel, Fat. Sci. Technol. 90 (7), 268-271 (1988)), is the Distribution and penetration into the skin of more crucial Meaning. Liposomes are therefore in distribution and penetration into the skin the ideal carrier system.
Bisher bekannte Liposomen haben aber trotz der genannten idealen Eigenschaften wesentliche Nachteile:So far known liposomes have despite the mentioned ideal characteristics significant disadvantages:
Liposomen klassischer Zusammensetzung sind aufgrund der üblicherweise eingesetzten hochreinen Ausgangsmaterialien - meist sind dies hochangereicherte Phosphatidylcholine - und des komplizierten Herstellungsprozesses wesentlich teurer als übliche Emulsionen mit weniger guten Eigenschaften.Liposomes of classical composition are due to the commonly used high purity starting materials - These are usually highly enriched phosphatidylcholines - and the complicated manufacturing process much more expensive than usual emulsions with less good properties.
Liposomen klassischer Zusammensetzung haben ein nur geringes Speichervermögen für lipophile Substanzen. Liposomen aus ungesättigten Phospholipiden können zwar ca. 10-30% ihres Gewichts an Triglyceriden aufnehmen, dies bedeutet aber selbst für eine sehr hochkonzentrierte Liposomendispersion mit 10% Liposomengrundstoff (in der Trockensubstanz) eine Endkonzentration von 1-3% Triglycerid in der Formulierung. In vergleichbaren Öl/Wasser- Emulsionen sind dagegen 10-20% lipophile Komponenten üblich.Liposomes of classical composition have only a minor one Storage capacity for lipophilic substances. liposomes from unsaturated phospholipids can indeed approx. Take up 10-30% of their weight in triglycerides, this But even means for a very highly concentrated Liposomal dispersion with 10% liposome base (in the Dry matter), a final concentration of 1-3% triglyceride in the formulation. In comparable oil / water Emulsions, however, are 10-20% lipophilic components common.
Ein weiterer gravierender Nachteil hinsichtlich des Einsatzes von Liposomen in Badeformulierungen ist die Tatsache, daß fertige liposomale Badeprodukte sehr viel Wasser enthalten (80% und mehr) und in dementsprechend große Gebinde (500-1000 ml) abgefüllt und konserviert werden müssen. Die Formulierungen sind trotz Konservierung nur beschränkt haltbar, da die Bestandteile der Liposomen zu Hydrolyse-Reaktionen und Oxidierbarkeit neigen und damit die Zusammensetzung während der Lagerung verändert wird. Sie sind daher nur beschränkt lagerfähig. Dies alles ist aus heutiger Sicht unrentabel und unpraktisch und hat bisher den wirtschaftlichen Durchbruch liposomaler Badepräparate verhindert. Das Problem kann auch damit nicht gelöst werden, daß z. B. gefriergetrocknete oder sprühgetrocknete Instant-Liposomen eingesetzt werden, da sie einerseits von der Herstellung sehr teuer und damit unwirtschaftlich sind, andererseits gerade flüssige lipophile Komponenten naturgemäß nicht oder nur sehr beschränkt enthalten können. Hinzu kommt, daß derartige Formulierungen ein besonders großes Volumen einnehmen und daher unvorteilhaft transportiert werden können.Another serious disadvantage regarding the Use of liposomes in bath formulations is the Fact that finished liposomal bath products very much Contain water (80% and more) and in accordingly large containers (500-1000 ml) bottled and preserved Need to become. The formulations are despite conservation only limited shelf life, since the components of the Liposomes to Hydrolysis Reactions and Oxidizability tend and thus the composition during storage is changed. They are therefore limited storable. All this is unprofitable from today's perspective and impractical and so far has the economic Breakthrough liposomal bath preparations prevented. The Problem can not be solved so that z. B. freeze-dried or spray-dried instant liposomes be used, since on the one hand from the production very expensive and therefore uneconomic, on the other hand just liquid lipophilic components naturally not included or only very limited can. In addition, such formulations a occupy a particularly large volume and therefore unfavorable can be transported.
Nun hat sich überraschend gezeigt, daß man die oben genannten Probleme elegant lösen oder umgehen kann, wenn man Phospholipidformulierungen, dadurch gekennzeichnet, daß sie Phosphatidylcholin (1), eine Ölkomponente (2), Alkohol (3), Stabilisator (4), Wirkstoff (5) und gegebenenfalls Hilfsstoff (6) enthalten, bei der Anrichtung des Bades oder Teilbades in das Badewasser gießt, wobei sich in situ die Bildung von mit Öl und mit Wirkstoffen beladenen Liposomen vollzieht.Now it has surprisingly been found that the above elegantly solve or circumvent these problems, when phospholipid formulations, characterized that they phosphatidylcholine (1), an oil component (2), alcohol (3), stabilizer (4), active substance (5) and optionally excipient (6), in the alignment of the bath or partial bath in the bath water pours, whereby in situ the formation of with oil and with active substances loaded liposomes.
Die genannten Hauptkomponenten der erfindungsgemäßen Phospholipidformulierungen (1) bis (6) sind:The said main components of the invention Phospholipid formulations (1) to (6) are:
- (1) Phosphatidylcholin: Produkte dieser Art sind unter unterschiedlichen Handelsbezeichnungen im Handel und werden von Lecithinverarbeitern hergestellt. Vorteilhafterweise werden pflanzliche, meist aus der Sojabohne gewonnene, oder tierische, meist aus Hühnerei gewonnene, Phosphatidylcholine eingesetzt.(1) Phosphatidylcholine: Products of this kind are under different trade names in the trade and are made by lecithin processors. advantageously, become vegetable, mostly from the soybean won, or animal, mostly from chicken egg, Phosphatidylcholines used.
- (2) Ölkomponente: Diese Komponente kann aus nativem Öl, (teil-)synthetischem Öl, Carbonsäureestern, flüssigen Wachsestern, öligen Kohlenwasserstoffen oder Mischungen derselben bestehen. Unter nativen Ölen versteht man Naturöle pflanzlichen oder tierischen Ursprungs. Pflanzliche Öle sind z. B. Sonnenblumenöl, Distelöl, Avocadoöl, Mandelöl, Sojaöl, Rizinusöl, Erdnußöl, Weizenkeimöl, Karottenöl, Aprikosenkernöl, Borretschöl, Nachtkerzenöl, Haselnußöl, Palmkernöl, Sesamöl, Leinöl, Macadamia-Nußöl, Maiskeimöl, Rüböl, Mohnöl, Pfirsichkernöl, Olivenöl, Walnußöl. Tierische Öle sind z. B. Nerzöl und Fischöl. (Teil-)synthetische Öle sind hauptsächlich Triglyceride, deren Säurekomponenten aus definierten oder Mischungen aus mittel- oder langkettigen Fettsäuren bestehen, z. B. Capronsäure, Caprinsäure, Stearinsäure, Isostearinsäure, Palmitinsäure, Ölsäure, Linolsäure, Ricinolsäure. Zu den synthetischen Ölen gehören auch die Silikonöle. Unter Carbonsäureestern sind z. B. Isopropylpalmitat, Isopropylmyristat, Isopropylstearat, Oleyloleat, Myristyllactat, Cetyllactat, 2-Ethylhexylpalmitat, Isooctylstearat, Hexyllaurat, Dibutyladipat, 2-Octyldecanol, Isopropyllinoleat zu verstehen. Flüssige Wachsester sind z. B. im Jojobaöl enthalten. Auch feste Wachsester sind verwendbar, wenn sie in den oben genannten flüssigen Ölen gelöst werden können. Ölige Kohlenwasserstoffe sind z. B. Paraffinöl, Heptamethylnonan.(2) Oil Component: This component may be of native oil, (partially) synthetic oil, carboxylic acid esters, liquid Waxy esters, oily hydrocarbons or mixtures consist of the same. By native oils one understands Natural oils of plant or animal origin. Vegetable oils are z. Sunflower oil, thistle oil, Avocado oil, almond oil, soybean oil, castor oil, peanut oil, wheat germ oil, Carrot oil, apricot kernel oil, borage oil, Evening primrose oil, hazelnut oil, palm kernel oil, sesame oil, linseed oil, Macadamia nut oil, corn oil, rapeseed oil, poppy seed oil, peach kernel oil, Olive oil, walnut oil. Animal oils are z. B. Mink oil and fish oil. Are (partial) synthetic oils mainly triglycerides whose acid components are made defined or mixtures of medium or long-chain Consist of fatty acids, eg. B. caproic acid, capric acid, Stearic acid, isostearic acid, palmitic acid, Oleic acid, linoleic acid, ricinoleic acid. To the synthetic ones Oils also include the silicone oils. Under carboxylic acid esters are z. Isopropyl palmitate, isopropyl myristate, Isopropyl stearate, oleyl oleate, myristyl lactate, cetyl lactate, 2-ethylhexyl palmitate, isooctyl stearate, hexyl laurate, Dibutyl adipate, 2-octyl decanol, isopropyl linoleate to understand. Liquid wax esters are z. In the Jojoba oil included. Also solid wax esters are usable if in the above liquid Oils can be dissolved. Oily hydrocarbons are z. For example, paraffin oil, heptamethylnonane.
- (3) Alkohol: Hierunter versteht man vorzugsweise Ethanol mit einem Gehalt von 90-100%. Es können aber auch andere geradkettige, verzweigtkettige Alkohole oder Polyalkohole wie z. B. Propanol, Isopropanol, 1.2-Propylenglykol, 1.3-Butylenglykol, Glycerin eingesetzt werden. Der Zusatz des Alkohols hat die Funktion, eine homogene Lösung bei der Mischung der Formulierungsbestandteile herzustellen, er hat aber auch den bekannten hautpflegenden Charakter, insbesondere wenn 1.2- Propylenglykol, 1.3-Butylenglykol oder Glycerin eingesetzt werden.(3) Alcohol: This is preferably understood to mean ethanol with a content of 90-100%. But it can also other straight-chain, branched-chain alcohols or Polyalcohols such. For example, propanol, isopropanol, 1,2-propylene glycol, 1.3-butylene glycol, glycerol used become. The addition of alcohol has the function, one homogeneous solution when mixing the formulation ingredients but he also has the well-known skin care character, especially when 1.2- Propylene glycol, 1.3-butylene glycol or glycerol used become.
- (4) Stabilisator: Der hier verwendete Stabilisator ist in der Regel Harnstoff. Er hat die Funktion, einerseits die Oxidationsbeständigkeit der erfindungsgemäßen Phospholipidformulierungen ganz wesentlich zu erhöhen, andererseits die optimale Bildung der Liposomen beim Eingießen in Wasser zu gewährleisten. Zum anderen ist Harnstoff ein für den Fachmann bekannter hautpflegender natürlicher Stoff, der Bestandteil der Haut ist und unter anderem auch den Wasserhaushalt der Haut positiv beeinflußt. Typische Stabilisatoren sind auch Monosaccharide wie z. B. Glucose, Fructose, Mannose, Galaktose, Sorbitol, Inositol und andere Saccharide. Selbstverständlich können auch Mischungen der genannten Stabilisatoren benutzt werden, wenn diese Vorteile bieten.(4) Stabilizer: The stabilizer used here is usually urea. He has the function, on the one hand the oxidation resistance of the phospholipid formulations according to the invention to significantly increase On the other hand, the optimal formation of liposomes in To ensure pouring in water. The other is Urea a well-known for the expert skin care natural substance that is part of the skin and Among other things, the water balance of the skin is positive affected. Typical stabilizers are also monosaccharides such as Glucose, fructose, mannose, galactose, Sorbitol, inositol and other saccharides. Of course may also be mixtures of said stabilizers be used if these offer benefits.
-
(5) Wirkstoff: Hierbei kann es sich um einen oder mehrere
kosmetisch wirksame Wirkstoffe oder um einen oder
mehrere pharmakologische Wirkstoffe handeln:
Kosmetische Wirkstoffe der erfindungsgemäßen Phospholipidformulierungen sind Fette, Vitamine (insbesondere A, B-Komplex, C, E sowie deren übliche Derivate wie z. B. Vitamin-A-palmitat, Vitamin-E-acetat), Provitamine wie β-Carotin, etherische Öle, selbstbräunende Substanzen wie Tyrosin; UV-Licht-Absorber wie z. B. Urocaninsäure und deren Ester, Hautschutzstoffe wie z. B. Ricinolsäurederivate, Phytosterole, Cholesterin, Cholesterylsulfat, Squalen, Squalan, Palmitinsäure, Stearinsäure, Isostearinsäure. Wirkstoffe wie Panthenol, Bisabolol, Pflanzenextrakte, tierische Extrakte, Linolsäureester, alpha- und gamma-Linolensäureester, Collagen- und Elastin-Hydrolysate und deren Kondensate mit Fettsäuren, Glutathion, Ceramid, Sphingolipide. Vielfach haben die oben genannten Ölkomponenten (2), wie z. B. pflanzliche, tierische Öle und Wachsester, auf Grund ihrer Zusammensetzung ebenfalls kosmetischen Wirkstoffcharakter.
Pharmazeutische Wirkstoffe der erfindungsgemäßen Phospholipidformulierungen sind Retinol und deren Ester, Vitamin-A-säure und deren Ester (Tretinoin), Isotretinoin, Retinoide allgemein, Antimykotika, Antiseptika wie Chlorhexidin, juckreizstillende Substanzen, nichtsteroidale Antirheumatika und deren Ester wie z. B. Salicylsäure, Salicylsäuremethylester; entzündungshemmende Mittel, durchblutungsfördernde Mittel wie z. B. Nicotinsäurebenzylester; Campher, Corticoide wie Hydrocortison, Betamethason, Triamcinolon, Dexamethason, Prednisolon; Heparin, Zytostatika, Antihistaminika, Antiallergika, Antibiotika wie z. B. Tetracyclin, Erythromycin, Gentamycin, Neomycin; antiparasitäre Mittel, Venenmittel, Wundbehandlungsmittel, Adstringentien, Antiaknemittel, Antipsoriatika, Aniseborrhoika, Antisebostatika, Keratolytika, Narbenbehandlungsmittel, Allantoin, Clotrimazol, Guajazulen, Hexylresorcin, Isoprenalin, Fumarsäure, Fumarsäureethylester, Fumarsäurediethylester, Dithranol, Ichthyol, Thymol, Rosmarinöl, Panthenol, Pantothensäure, Kamillenextrakt, Hamamelisextrakt, Salbeiöl, Eukalyptusöl, Fichtennadelöl, Wacholderbeeröl, Baldrianöl, Baldrianextrakt, Eichenrindeextrakt, Weizenkleieextrakt, Kiefernnadelöl, Borneol, Menthol, Schafgarbenblütenextrakt, Limonen, Heublumenextrakt, Molkepulver, Hopfenextrakt, Lavendelöl, Tannin, Aesculin, Aescin, Salicylamid, Latschenkieferextrakt, Nicotinsäuremethylester, Nicotinsäureethylester, Salicylsäurenicotinat, Salicylsäureglycolester, Estradiol, Dichlorophen, Undecylensäure, Colecalciferol, Placentaextrakt, Thymusextrakt, Benzalkoniumchlorid, Griseofulvin, Nystatin, Amphotericin B, Clotrimazol, Miconazol, Econazol, Tioconazol, Ketoconazol, Isoconazol, Coffein, Ibuprofen, Indometacin, Etofenamat, Diclophenac, Flufenaminsäure, Silibinin, Silymarin, Linolsäure, alpha-Linolensäure, gamma-Linolensäure, di-homo-gamma-Linolensäure, Eicosapentaensäure, Minoxidil, Superoxiddismutase.(5) Active substance: This may be one or more cosmetically active substances or one or more pharmacologically active substances:
Cosmetic active ingredients of the phospholipid formulations according to the invention are fats, vitamins (in particular A, B complex, C, E and their customary derivatives such as, for example, vitamin A palmitate, vitamin E acetate), provitamins such as β-carotene, essential oils , self-tanning substances such as tyrosine; UV light absorber such. As urocaninic acid and its esters, skin protection agents such. As ricinoleic acid derivatives, phytosterols, cholesterol, cholesteryl sulfate, squalene, squalane, palmitic acid, stearic acid, isostearic acid. Active ingredients such as panthenol, bisabolol, plant extracts, animal extracts, linoleic acid esters, alpha- and gamma-linolenic acid esters, collagen and elastin hydrolysates and their condensates with fatty acids, glutathione, ceramide, sphingolipids. In many cases, the above-mentioned oil components (2), such as. As vegetable, animal oils and wax esters, due to their composition also cosmetic active ingredient character.
Pharmaceutical agents of the phospholipid formulations according to the invention are retinol and its esters, vitamin A acid and its esters (tretinoin), isotretinoin, retinoids in general, antimycotics, antiseptics such as chlorhexidine, antipruritic substances, non-steroidal anti-inflammatory drugs and their esters such. Salicylic acid, salicylic acid methyl ester; anti-inflammatory agents, circulation-promoting agents such. B. nicotinic acid benzyl ester; Camphor, corticoids such as hydrocortisone, betamethasone, triamcinolone, dexamethasone, prednisolone; Heparin, cytostatics, antihistamines, antiallergic agents, antibiotics such. Tetracycline, erythromycin, gentamycin, neomycin; antiparasitic agents, venom agents, wound dressings, astringents, antacids, antipsoriatics, aniseborrhoids, antisecretants, keratolytics, scar treatment agents, allantoin, clotrimazole, guaiaculen, hexylresorcinol, isoprenaline, fumaric acid, fumaric acid ethyl ester, diethyl fumarate, dithranol, ichthyol, thymol, rosemary oil, panthenol, pantothenic acid, chamomile extract , witch hazel extract, sage oil, eucalyptus oil, pine needle oil, juniper berry oil, valerian oil, valerian extract, oak bark extract, wheat bran, pine oil, borneol, menthol, yarrow flower extract, limonene, Heublumenextrakt, whey powder, hops extract, lavender oil, tannin, esculin, aescin, salicylamide, mountain pine extract, methyl nicotinate, ethyl nicotinate , Salicylic acid nicotinate, salicylic acid glycol ester, estradiol, dichlorophen, undecylenic acid, colecalciferol, placental extract, thymus extract, benzalkonium chloride, griseofulvin, nystatin, amphotericin B, clotrimazole, Mi conazole, econazole, tioconazole, ketoconazole, isoconazole, caffeine, ibuprofen, indomethacin, etofenamate, diclophenac, flufenamic acid, silibinine, silymarin, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, di-homo-gamma-linolenic acid, eicosapentaenoic acid, minoxidil, superoxide dismutase. - (6) Hilfsstoff: Unter einem gegebenenfalls mit zu formulierenden Hilfsstoff der erfindungsgemäßen Phospholipidformulierungen sind z. B. Duftstoffe, Parfümöle, Antioxidantien wie z. B. Ascorbinsäure, Ascorbinsäurepalmitat, Butylhydroxytoluol, Butylhydroxyanisol, Propylgallat, Vitamin E, Vitamin-E-acetat, Vitamin-E-palmitat, Antioxidans-Synergisten wie z. B. EDTA, 1-Hydroxyethan- 1.1-diphosphonsäure, Citronensäure, Fumarsäure, Harnsäure und färbende Substanzen sowie deren Mischungen untereinander zu verstehen.(6) Excipient: Under an optionally to be formulated Excipient of the phospholipid formulations according to the invention are z. As perfumes, perfume oils, antioxidants such as As ascorbic acid, ascorbic acid palmitate, Butylhydroxytoluene, butylhydroxyanisole, propyl gallate, Vitamin E, vitamin E acetate, vitamin E palmitate, Antioxidant synergists such. B. EDTA, 1-hydroxyethane 1,1-diphosphonic acid, citric acid, fumaric acid, Uric acid and coloring substances and mixtures thereof to understand each other.
Entsprechend den gewünschten Gehalten der einzusetzenden Wirkstoffe werden die Gehalte der anderen Komponenten der erfindungsgemäßen Phospholipidformulierungen angepaßt. Die Gehalte der Einzelkomponenten der erfindungsgemäßen Phospholipidformulierungen können daher in folgenden Grenzen variieren:According to the desired contents of the used Active substances are the contents of other components the phospholipid formulations according to the invention customized. The contents of the individual components of the invention Phospholipid formulations can therefore be used in the following limits vary:
Vorzugsweise betragen die Gehalte der Komponenten der erfindungsgemäßen Phospholipidformulierungen:Preferably, the contents of the components are Phospholipid formulations according to the invention:
Typische Zusammensetzungen der erfindungsgemäßen Phospholipidformulierungen sind:Typical compositions of the phospholipid formulations according to the invention are:
Die erfindungsgemäßen Phospholipidformulierungen können dabei vollständig aus Naturstoffen oder naturidentischen Stoffen aufgebaut sein, wie die folgende Formulierung illustriert.The phospholipid formulations according to the invention can completely made of natural materials or nature-identical Be constructed like the following formulation illustrated.
Das Verfahren zur Herstellung der oben aufgeführten erfindungsgemäßen Phospholipidformulierungen ist dadurch gekennzeichnet, daß man nacheinander Phosphatidylcholin (1), Alkohol (3), Stabilisator (4), Wirkstoff (5), Hilfsstoff (6) bei 20 bis 60°C, vorzugsweise bei 20 bis 40°C, mittels eines Ankerrührwerks oder eines anderen üblichen Rührwerks bis zur Lösung rührt und am Schluß die Ölkomponente (2) zumischt. The process for the preparation of the invention listed above Phospholipid formulations is thereby characterized in that successively phosphatidylcholine (1), alcohol (3), stabilizer (4), active substance (5), Excipient (6) at 20 to 60 ° C, preferably at 20 to 40 ° C, by means of an anchor agitator or another usual agitator stirs until solution and at the end the oil component (2) admixed.
Die Zubereitung des Teil- oder Vollbades mit Hilfe der erfindungsgemäßen Phospholipidformulierungen ist dadurch gekennzeichnet, daß man die Phospholipidformulierungen einfach in das Badewasser gießt oder mit dem einlaufenden Wasser vermischt, wobei beliebige Konzentrationen eingestellt werden können.The preparation of the partial or full bath with the help of Phospholipidformulierungen invention is characterized characterized in that the phospholipid formulations just pour in the bath water or with the incoming water is mixed, with any concentrations can be adjusted.
Das Verfahren der Herstellung eines (Teil-)Bades unter Anwendung der erfindungsgemäßen Phospholipidformulierungen zeigt keinen der oben für konventionelle Badezubereitungen erwähnten Nachteile. Dies kommt insbesondere dem Endverbraucher zugute.The method of producing a (partial) bath under Application of the Phospholipidformulierungen invention does not show any of the above for conventional bathing preparations mentioned disadvantages. This comes in particular benefit the end user.
Die Hauptvorteile der erfindungsgemäßen Phospholipidformulierungen sind:The main advantages of the phospholipid formulations according to the invention are:
Die erfindungsgemäßen Phospholipidformulierungen unterscheiden sich äußerlich nicht von konventionellen Produkten und können auch in gleicher Weise benutzt werden, d. h. die fertigen liposomalen Badezubereitungen bilden sich durch bloßes Eingießen der erfindungsgemäßen Phospholipidformulierungen in Wasser. Komplizierte Schritte zur Herstellung der vorliegenden mit Ölkomponente und Wirkstoff beladenen Liposomen entfallen völlig. Die erfindungsgemäßen Phospholipidformulierungen werden durch einfaches Mischen bzw. Lösen der Einzelkomponenten hergestellt. Dies kann bei Raumtemperatur mit einem üblichen Ankerrührwerk oder einem anderen geeigneten Rührwerk geschehen, der Mischungsvorgang kann aber auch durch Zuhilfenahme einer Wärmequelle bei erhöhter Temperatur bis maximal 60°C, vorzugsweise 20 bis 40°C durchgeführt werden. Die Herstellung der liposomalen Badezubereitungen ist daher besonders kostengünstig.The phospholipid formulations according to the invention differ outwardly not from conventional products and can also be used in the same way d. H. the finished liposomal bath preparations form by mere pouring the invention Phospholipid formulations in water. complicated Steps for making the present with oil component and drug-loaded liposomes omitted completely. The phospholipid formulations according to the invention be by simply mixing or dissolving the individual components manufactured. This can be done at room temperature with a standard anchor stirrer or another suitable agitator happen, the mixing process but also by the aid of a heat source at elevated temperature to a maximum of 60 ° C, preferably 20 be carried out to 40 ° C. The production of liposomal bathing preparations is therefore particularly inexpensive.
Liposomen werden erst in situ beim Eingießen der erfindungsgemäßen Phospholipidformulierungen in das Badewasser an Ort und Stelle gebildet. Es bilden sich dabei besonders hoch mit Ölkomponente und Wirkstoff beladene Liposomen aus. Sie gehören zu den sogenannten lipidreichen liposomalen Systemen.Liposomes are first in situ when pouring the invention Phospholipid formulations in the bathwater formed on the spot. It is formed here particularly high loaded with oil component and active ingredient Liposomes out. They belong to the so-called lipid-rich liposomal systems.
Die erfindungsgemäßen Phospholipidformulierungen werden wasserfrei hergestellt und sind damit hydrolytisch stabil, wobei Restwassermengen, die naturgemäß in den Einzelkomponenten enthalten sind, keinen Einfluß auf die Lagerstabilität haben. Eine Oxidationsanfälligkeit der Phospholipidformulierungen ist durch Anwesenheit des Stabilisators, gegebenenfalls auch durch den Hilfsstoff, der Antioxidantien und gegebenenfalls Antioxidans- Synergisten enthält, bei geschlossenem Gefäß, das aus diffusionssicherem Material wie z. B. Glas bestehen sollte, auch über Jahre nicht gegeben.The phospholipid formulations according to the invention are produced anhydrous and are thus hydrolytically stable, being residual amounts of water, of course, in the individual components contain no influence on the Have storage stability. An oxidation susceptibility of Phospholipid formulations are due to the presence of the Stabilizer, optionally also by the excipient, the antioxidants and optionally antioxidant Synergist contains, with the vessel closed, off diffusion-proof material such. B. glass should not be given even for years.
Für ein gewöhnliches Vollbad reichen je nach Dosierung der Wirkstoffe 10-100 ml der erfindungsgemäßen Phospholipidformulierungen aus. Dies ist für eine liposomale Badezubereitung sehr wenig.For an ordinary full bath depending on dosage of the active ingredients 10-100 ml of the phospholipid formulations according to the invention out. This is for a liposomal Bathing preparation very little.
Die erfindungsgemäßen Phospholipidformulierungen lassen sich bei Bedarf ausschließlich aus Naturstoffen herstellen.Leave the phospholipid formulations according to the invention If necessary, only be made from natural substances.
Die erfindungsgemäßen Phospholipidformulierungen benötigen für ihre Anwendung keinen konventionellen Emulgator. Ein Emulgator wäre, insbesondere in größeren Mengen, sogar geradezu schädlich für die Ausbildung der späteren liposomalen Strukturen, da Emulgatoren im allgemeinen die Bilayer der Liposomen zerstören (H. Hauser, Chimia 39, 252 (1985)).The phospholipid formulations according to the invention require for their application no conventional emulsifier. An emulsifier would be, especially in larger quantities, even downright harmful to the training of the later liposomal structures, since emulsifiers in the general destroy the bilayer of the liposomes (H. Hauser, Chimia 39, 252 (1985)).
Die Liposomengrundstoffe wie das in den erfindungsgemäßen Phospholipidformulierungen verwendete Phosphatidylcholin sind dafür bekannt, daß sie selbst in oder durch die Haut penetrieren, auf der anderen Seite aber vollständig ohne Nebenwirkungen sind, da sie körpereigen vorkommen. Sie zeigen im Gegenteil sehr positive Wirkungen auf die Physiologie der Haut, wie z. B. eine Reduzierung des transepidermalen Wasserverlustes. Phosphatidylcholin ist daher auch als kosmetischer Wirkstoff anzusehen (H. Lautenschläger, J. Röding und M. Ghyczy, Seifen, Öle, Fette, Wachse 114 (14), 531-534 (1988)). So werden Liposomen heute als Bilayerquelle angesehen, die die bei strapazierter Haut geschädigten Bilayer der Hornschicht wiederherstellen können, ein Effekt der bei Verwendung konventioneller Emulsionen nicht eintreten kann. Ein weiterer Vorteil der Penetration ist die Einschleusung kosmetischer Wirkstoffe in die Hornschicht der Haut, die eine Depotfunktion hat, und der Transport pharmakologisch aktiver Stoffe in und durch die Haut. Die Stoffe gelangen dabei auch an Körperstellen, die mit üblichen Formulierungen nur schwer erreichbar sind. Dies ist z. B. wichtig bei Teilbädern mit antimykotisch wirksamen Wirkstoffen gegen Mykosen, insbesondere den Nagelmykosen.The liposome bases such as that in the inventive Phospholipid formulations used phosphatidylcholine are known to be themselves in or penetrate through the skin, but on the other side are completely without any side effects, as they are the body's own occurrence. On the contrary, they show very positive Effects on the physiology of the skin such. Legs Reduction of transepidermal water loss. phosphatidylcholine is therefore also a cosmetic active ingredient (H. Lautenschläger, J. Röding and M. Ghyczy, soaps, oils, fats, waxes 114 (14), 531-534 (1988)). This is how liposomes are today used as bilayer sources considered that the damaged on damaged skin Bilayer can restore the horny layer, a Effect of using conventional emulsions can not occur. Another advantage of penetration is the introduction of cosmetic agents in the horny layer of the skin, which has a depot function and transport of pharmacologically active substances in and through the skin. The substances also get there at body parts, with usual formulations only are difficult to reach. This is z. B. important Partial baths with antifungal active ingredients against mycoses, especially nail mycoses.
Phosphatidylcholin wirkt bekanntermaßen nicht entfettend, da es sich im Gegenteil teilweise mit dem Keratin der Hornschicht zu Komplexverbindungen verbindet. Dies bewirkt eine starke rückfettende Wirkung. Diese rückfettende Wirkung ist besonders ausgeprägt, da die erfindungsgemäßen Phospholipidformulierungen keinen konventionellen, d. h. naturgemäß entfettenden Emulgator enthalten.Phosphatidylcholine is known not to degrease, on the contrary, it is partly with the keratin the horny layer connects to complex compounds. This causes a strong moisturizing effect. This moisturizing Effect is particularly pronounced since the invention Phospholipid formulations no conventional, d. H. naturally degreasing emulsifier contain.
Die Verwendung von Phosphatidylcholin in den erfindungsgemäßen Phospholipidformulierungen hat den Vorteil, daß diese Verbindung eine extrem niedrige Micellenkonzentration besitzt (R. Smith und C. Tanford, J. Mol. Biol. 67, 75-83 (1972)) und daher im Vergleich zu konventionellen Emulgatoren, deren kritische Micellenkonzentration um mehrere Zehnerpotenzen höher liegen, keinerlei irritierende Wirkung auf die Haut ausübt.The use of phosphatidylcholine in the invention Phospholipid formulations have the advantage that this compound has an extremely low micelle concentration has (R. Smith and C. Tanford, J. Mol. Biol. 67, 75-83 (1972)) and therefore in comparison to conventional emulsifiers whose critical micelle concentration by several orders of magnitude higher, no irritating effect on the skin.
Die erfindungsgemäßen Phospholipidformulierungen benötigen für ihre Haltbarkeit keinerlei Konservierungsmittel und sind daher besonders hautfreundlich. Konservierungsmittel- Allergien oder -Empfindlichkeiten sind daher nicht zu befürchten. Deshalb sind die erfindungsgemäßen Phospholipidformulierungen insbesondere für Menschen mit sehr empfindlicher Haut, für Allergiker, Psoriatiker, Atopiker, Neurodermitiker und andere unter Dermatosen, wie z. B. der Ichthyose, leidende Menschen geeignet. Die erfindungsgemäßen Phospholipidformulierungen können auch direkt zur Behandlung dieser Krankheiten eingesetzt werden, wenn entsprechende pharmazeutische Wirkstoffe in die erfindungsgemäßen Phospholipidformulierungen eingearbeitet sind. Auch die Behandlung von Sonnenbränden läßt sich sehr vorteilhaft gerade mit stark linol- und linolensäurehaltigen Phospholipidformulierungen durchführen.The phospholipid formulations according to the invention require no preservatives for their durability and are therefore particularly kind to the skin. preservative- Allergies or sensitivities are therefore not to be feared. Therefore, the invention Phospholipid formulations especially for People with very sensitive skin, for allergy sufferers, Psoriatiker, Atopiker, Neurodermitiker and others under Dermatoses, such. Eg ichthyosis, suffering people suitable. The phospholipid formulations according to the invention can also be used directly to treat these diseases be used if appropriate pharmaceutical Active substances in the phospholipid formulations according to the invention are incorporated. Also the treatment sunburns can be very beneficial straight with strong linoleic and linolenic acid phospholipid formulations carry out.
Die Liposomen und die darin enthaltenen Öl- und Wirkstoffkomponenten, die bei Anwendung der erfindungsgemäßen Phospholipidformulierungen entstehen, sind so fein im Wasser verteilt, daß eine sonst bei konventionellen Ölbädern zu beobachtende Aufrahmung der Ölkomponente nicht stattfindet. Die Problematik der nach Ablassen des Badewassers zurückbleibenden schwer zu entfernenden Fettränder gibt es daher bei Anwendung der erfindungsgemäßen Phospholipidformulierungen nicht.The liposomes and the oil and drug components contained therein, when using the inventive Phospholipidformulierungen arise are so finely distributed in the water, that one else in conventional Oil baths to be observed Oil component does not take place. The problem of after draining the bathwater remaining heavy There are therefore to be removed fat edges in use not the phospholipid formulations according to the invention.
Die Liposomen, die bei Anwendung der erfindungsgemäßen Phospholipidformulierungen entstehen, besitzen je nach Zusammensetzung der Formulierung eine durchschnittliche Größe von 100-2000 nm, d. h. die Größe ist durch Art und Menge der Einzelkomponenten steuerbar.The liposomes, when using the inventive Phospholipidformulierungen arise, depending on Composition of the formulation an average Size of 100-2000 nm, d. H. the size is by type and quantity of the individual components controllable.
Je nach Zusammensetzung der Komposition können sehr unterschiedlich geformte Vesikel entstehen:Depending on the composition of the composition can be very different shaped vesicles arise:
- (a) Klassische uni-, oligo-, multi-lamellare Liposomen bei hohen Gehalten an Phosphatidylcholin (1) und niedrigen Gehalten der Ölkomponente (2) und des Wirkstoffs (5); (a) Classic uni-, oligo-, multi-lamellar liposomes at high levels of phosphatidylcholine (1) and low Contents of the oil component (2) and the active ingredient (5);
- (b) Sogenannte Propeller-Liposomen bei vergleichbaren Gehalten an Phosphatidylcholin (1) und Ölkomponente (2) und/oder Wirkstoff (5). Propeller-Liposomen sind dadurch gekennzeichnet, daß sie aus Aggregaten von Öltröpfchen und klassischen Liposomen bestehen.(b) so-called propeller liposomes in comparable Levels of phosphatidylcholine (1) and oil component (2) and / or active ingredient (5). Propeller liposomes are thereby characterized in that they are aggregates of oil droplets and classic liposomes.
- (c) Chylomikronenartige Liposomen bei hohen Gehalten an Ölkomponente (2) und Wirkstoffes (5) und niedrigen Gehalten an Phosphatidylcholin (1). Chylomikronenartige Liposomen zeichnen sich dadurch aus, daß sie bei Beibehaltung der lamellaren liposomalen Struktur, die größtenteils durch das Phosphatidylcholin (1) gebildet wird, eine mehr oder weniger stark ausgeprägte ölige Innenphase besitzen, die durch die Ölkomponente (2) bzw. den Wirkstoff (5) gebildet wird. Im Extremfall kann die Innenphase völlig mit amphiphilen und lipophilen Komponenten ausgefüllt sein. Diese Zubereitungen sind besonders interessant, da sie durch Verwendung von nur wenig Phosphatidylcholin, im Extremfall 5 Gew.-%, sehr preiswert sind und vorteilhaft mit kosmetisch und pharmakologisch wirksamen Eiweißhydrolysatkondensaten als Wirkstoffkomponente (5) kombiniert werden können. Als Wirkstoffkomponenten können z. B. Palmitoyl-collagenhydrolysat, Capryloylcollagenhydrolysat, Undecenoylcollagenhydrolysat sowie die acylierten Hydrolysate des Caseins, des Keratins und des Hydroxyprolins eingesetzt werden. Selbstverständlich können diesbezüglich auch definierte Reinsubstanzen wie z. B. die N-Palmitoylderivate der Glutaminsäure, des Arginins, der Asparaginsäure, des Lysins, des Serins, des Isoleucins verwendet werden.(c) Chylomicron-like liposomes at high levels Oil component (2) and active ingredient (5) and low levels on phosphatidylcholine (1). Chylomikronenartige Liposomes are characterized by their retention lamellar liposomal structure, mostly formed by the phosphatidylcholine (1) is, a more or less pronounced oily Possess internal phase, which by the oil component (2) or the active ingredient (5) is formed. In extreme cases The inner phase can be completely amphiphilic and lipophilic Components filled. These preparations are particularly interesting as they are made by using only a little phosphatidylcholine, in extreme cases 5% by weight, are very cheap and beneficial with cosmetic and pharmacologically active protein hydrolyzate condensates as active ingredient component (5) can be combined. As active ingredient components z. Palmitoyl collagen hydrolyzate, Capryloyl collagen hydrolyzate, undecenoyl collagen hydrolyzate as well as the acylated hydrolyzates of Caseins, keratin and hydroxyproline become. Of course, in this regard too defined pure substances such. B. the N-palmitoyl derivatives glutamic acid, arginine, aspartic acid, of lysine, serine, isoleucine become.
Welche Art von liposomalen Vesikeln gebildet werden, ist daher stark vom Zweck des Einsatzes der erfindungsgemäßen Phospholipidformulierungen bestimmt, da hiervon die zu wählende Zusammensetzung abhängig ist.What kind of liposomal vesicles are formed is therefore strongly dependent on the purpose of the use of the invention Phospholipidformulierungen determined because of this the composition to be selected is dependent.
Je nach Zusammensetzung der erfindungsgemäßen Phospholipidformulierungen können auch Mischungen von klassischen Liposomen, Propeller-Liposomen und Chylomikronenartigen Liposomen entstehen.Depending on the composition of the phospholipid formulations according to the invention can also mixes of classic Liposomes, propeller liposomes and chylomicron-like Liposomes arise.
Die Herstellung der erfindungsgemäßen Phospholipidformulierungen und ihre Anwendung bei Nutzung unterschiedlicher Komponenten wird in den folgenden Beispielen illustriert. Das in den Beispielen verwendete Phosphatidylcholin ist ca. 90%ig angereichert, stammt aus der Sojabohne und ist im Handel unter dem Namen Phospholipon 90 erhältlich. Ähnliche Produkte sind auch unter anderen Namen, z. B. Lipoid S 100, Epikuron 200, Sternlipid PC-90, käuflich. Selbstverständlich lassen sich auch niedrig konzentriertere Produkte einsetzen, wenn sie mit den übrigen Komponenten kompatibel sind. Die den Komponenten vor- oder nachgestellten eingeklammerten Zahlen von (1) bis (6) entsprechen der in der Beschreibung angegebenen Klassifizierung: (1) für Phosphatidylcholin, (2) für Ölkomponente, (3) für Alkohol, (4) für Stabilisator, (5) für Wirkstoff und (6) für Hilfsstoff, wobei wie in Beschreibung ausgeführt, die Komponenten wiederum aus Mischungen von Einzelkomponenten bestehen können.The preparation of the phospholipid formulations according to the invention and their application when using different Components will be in the following examples illustrated. The phosphatidylcholine used in the examples is about 90% enriched, comes from of soybean and is commercially available under the name phospholipon 90 available. Similar products are too under other names, eg. B. Lipoid S 100, Epikuron 200, Star lipid PC-90, commercially available. Of course, let also use low-concentrated products, if they are compatible with the other components. The parenthesized or preceded components Numbers from (1) to (6) correspond to those in the classification given in the description: (1) for Phosphatidylcholine, (2) for oil component, (3) for Alcohol, (4) stabilizer, (5) active ingredient and (6) for excipient, where, as described, the components in turn from mixtures of Individual components may exist.
Die Dosierung beträgt etwa 50 ml Formulierung pro Vollbad, wobei die Wassermenge ca. 150-200 l beträgt. Die Formulierung wird entweder in das einlaufende Wasser gegossen oder unter Verteilung mit der Hand in das bereitstehende Wasser gegeben, wobei sich das Wasser schwach milchig trübt. Die Wassertemperatur ist beliebig und beträgt im Regelfall etwa 35-45°C. Die Formulierung kann auch für Teilbäder genutzt werden, wobei entsprechend weniger Formulierung eingesetzt wird. Bei besonders stark wirkenden Wirkstoffkomponenten wird die Dosierung zweckmäßigerweise gesenkt.The dosage is about 50 ml of formulation per Full bath, the amount of water is about 150-200 l. The wording is either in the incoming Water poured or under distribution by hand in given the available water, with the Water slightly cloudy milky. The water temperature is arbitrarily and is usually about 35-45 ° C. The Formulation can also be used for partial baths, with correspondingly less formulation used becomes. For particularly strong active ingredients the dosage is conveniently lowered.
Herstellung und Verwendung der folgenden Beispiele ist analog zu Beispiel 1:Preparation and use of the following examples is analogously to Example 1:
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19904021083 DE4021083C2 (en) | 1990-07-03 | 1990-07-03 | Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19904021083 DE4021083C2 (en) | 1990-07-03 | 1990-07-03 | Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths |
Publications (2)
Publication Number | Publication Date |
---|---|
DE4021083A1 true DE4021083A1 (en) | 1992-01-23 |
DE4021083C2 DE4021083C2 (en) | 1995-08-17 |
Family
ID=6409531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19904021083 Expired - Lifetime DE4021083C2 (en) | 1990-07-03 | 1990-07-03 | Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE4021083C2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686509A1 (en) * | 1992-01-29 | 1993-07-30 | Oreal | COSMETIC COMPOSITION INTENDED TO BE ADDITIONED TO THE WATER OF A BATH. |
DE4205548A1 (en) * | 1992-02-24 | 1993-08-26 | Merz & Co Gmbh & Co | BATHING AND SHOWER SUPPLEMENT WITH VESIGN-FORMING PROPERTIES, ITS MANUFACTURE AND USE |
DE4322158A1 (en) * | 1993-07-03 | 1995-01-12 | Rhone Poulenc Rorer Gmbh | Phospholipidic composition and use of such a composition |
WO1995031172A1 (en) * | 1994-05-16 | 1995-11-23 | Phares Pharmaceutical Holland B.V. | Liposome forming compositions |
WO1997042937A1 (en) * | 1996-05-10 | 1997-11-20 | Yamanouchi Europe B.V. | Instant vesicular product |
DE19735518C1 (en) * | 1997-08-16 | 1999-03-11 | Friedrun Geier | Rinsable emulsions for use as tallow-dissolving preparations |
DE19904801A1 (en) * | 1999-02-05 | 2000-08-10 | Klossner Axel | Agent containing urea, sulfur and Calendula extract, useful for topical treatment of skin disorders, especially neurodermatitis |
WO2001017484A2 (en) * | 1999-09-07 | 2001-03-15 | D.T.R. Dermal Therapy Research Inc. | Topical urea composition |
DE10124475A1 (en) * | 2001-05-19 | 2002-11-21 | Beiersdorf Ag | Cosmetic or dermatological composition containing ketohexose, useful for treating e.g. inflammation, pigment disorders, and skin aging, promotes barrier function |
DE10133202A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
WO2004108107A1 (en) * | 2003-06-10 | 2004-12-16 | Henkel Kommanditgesellschaft Auf Aktien | Skin preparation |
WO2006000196A1 (en) * | 2004-06-28 | 2006-01-05 | Trommsdorff Gmbh & Co. Kg | Mlv cosmetic product |
DE102010054461A1 (en) * | 2010-12-14 | 2012-06-14 | Merz Pharma Gmbh & Co. Kgaa | Liposome-forming aqueous bath preparations with high active ingredient content and their cosmetic / dermatological / medical application |
US20130156835A1 (en) * | 2010-04-16 | 2013-06-20 | Alberto Sardo | Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19852508C2 (en) * | 1998-11-16 | 2002-09-26 | Georg Huebner | Use of the unsaponified components from avocado |
DE10347487A1 (en) * | 2003-09-30 | 2005-04-21 | Kneipp Werke Kneipp Mittel Zen | Cosmetic or dermatological composition for topical use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0130577A2 (en) * | 1983-06-29 | 1985-01-09 | Daiichi Seiyaku Co., Ltd. | Method for producing liposomes |
CH669535A5 (en) * | 1986-04-22 | 1989-03-31 | Oreal |
-
1990
- 1990-07-03 DE DE19904021083 patent/DE4021083C2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0130577A2 (en) * | 1983-06-29 | 1985-01-09 | Daiichi Seiyaku Co., Ltd. | Method for producing liposomes |
CH669535A5 (en) * | 1986-04-22 | 1989-03-31 | Oreal |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686509A1 (en) * | 1992-01-29 | 1993-07-30 | Oreal | COSMETIC COMPOSITION INTENDED TO BE ADDITIONED TO THE WATER OF A BATH. |
WO1993014738A1 (en) * | 1992-01-29 | 1993-08-05 | L'oreal | Cosmetic composition for adding to bath water |
DE4205548A1 (en) * | 1992-02-24 | 1993-08-26 | Merz & Co Gmbh & Co | BATHING AND SHOWER SUPPLEMENT WITH VESIGN-FORMING PROPERTIES, ITS MANUFACTURE AND USE |
EP0557825A2 (en) * | 1992-02-24 | 1993-09-01 | Merz & Co. GmbH & Co. | Bath and shower additives with vesicle forming properties, preparation and use thereof |
EP0557825A3 (en) * | 1992-02-24 | 1995-02-01 | Merz & Co Gmbh & Co | Bath and shower additives with vesicle forming properties, preparation and use thereof |
DE4205548C3 (en) * | 1992-02-24 | 1998-07-23 | Merz & Co Gmbh & Co | Bath and shower additive with vesicle-forming properties, its production and use |
DE4322158A1 (en) * | 1993-07-03 | 1995-01-12 | Rhone Poulenc Rorer Gmbh | Phospholipidic composition and use of such a composition |
WO1995031172A1 (en) * | 1994-05-16 | 1995-11-23 | Phares Pharmaceutical Holland B.V. | Liposome forming compositions |
WO1997042937A1 (en) * | 1996-05-10 | 1997-11-20 | Yamanouchi Europe B.V. | Instant vesicular product |
DE19735518C1 (en) * | 1997-08-16 | 1999-03-11 | Friedrun Geier | Rinsable emulsions for use as tallow-dissolving preparations |
DE19904801A1 (en) * | 1999-02-05 | 2000-08-10 | Klossner Axel | Agent containing urea, sulfur and Calendula extract, useful for topical treatment of skin disorders, especially neurodermatitis |
WO2001017484A2 (en) * | 1999-09-07 | 2001-03-15 | D.T.R. Dermal Therapy Research Inc. | Topical urea composition |
WO2001017484A3 (en) * | 1999-09-07 | 2001-09-27 | D T R Dermal Therapy Res Inc | Topical urea composition |
DE10124475A1 (en) * | 2001-05-19 | 2002-11-21 | Beiersdorf Ag | Cosmetic or dermatological composition containing ketohexose, useful for treating e.g. inflammation, pigment disorders, and skin aging, promotes barrier function |
DE10133202A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
WO2004108107A1 (en) * | 2003-06-10 | 2004-12-16 | Henkel Kommanditgesellschaft Auf Aktien | Skin preparation |
WO2006000196A1 (en) * | 2004-06-28 | 2006-01-05 | Trommsdorff Gmbh & Co. Kg | Mlv cosmetic product |
US20130156835A1 (en) * | 2010-04-16 | 2013-06-20 | Alberto Sardo | Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
DE102010054461A1 (en) * | 2010-12-14 | 2012-06-14 | Merz Pharma Gmbh & Co. Kgaa | Liposome-forming aqueous bath preparations with high active ingredient content and their cosmetic / dermatological / medical application |
WO2012079717A2 (en) | 2010-12-14 | 2012-06-21 | Merz Pharma Gmbh Co. Kgaa | Liposome-forming aqueous bath preparations having a high proportion of active substance and use of said preparations |
Also Published As
Publication number | Publication date |
---|---|
DE4021083C2 (en) | 1995-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1513492B1 (en) | Microemulsions having a binary phase differentiability and active substance differentiability, the production thereof and their use, particularly for the topical supply of oxygen | |
DE69232914T2 (en) | Topical preparation containing a suspension of solid lipid particles | |
EP1628626B2 (en) | Compositions for the targetted release of fragrances and aromas | |
DE4021082C2 (en) | High lipid-containing skin treatment agent using a bilayer-containing system, organic acid salts, alcohol and stabilizer | |
DE3853191T2 (en) | Drug carrier. | |
EP2363108B1 (en) | Foam formulation containing at least one triterpenoid | |
EP1347734B2 (en) | Vesicle forming skin oil containing w/o-emulsifiers with a hydrophilic-lipophilic balance of 2-5.9, method for the production and use thereof | |
DE4021083C2 (en) | Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths | |
DE3713493A1 (en) | COSMETIC OR PHARMACEUTICAL AGENT BASED ON AN AQUEOUS DISPERSION OF LIPID BALLS | |
WO2010105842A2 (en) | Preparation for external application | |
DE19640092A1 (en) | Structures with lipid double membranes, in the lipophilic area of which longer-chain molecules are immersed or which are docked to such molecules through hydrophobic interactions | |
DE3713494A1 (en) | METHOD FOR PRODUCING A DISPERSION OF LIPID BALLS IN AN AQUEOUS PHASE AND DISPERSIONS AVAILABLE ACCORDING TO THIS METHOD | |
KR20110076068A (en) | Vesicle having self-emulsifying nano liposome and multilayer liquid crystal, a preparation method therof and its use | |
DE69119400T2 (en) | SYSTEM BASED ON A LIPID FORMULATION | |
EP0557825B1 (en) | Bath and shower additives with vesicle forming properties, preparation and use thereof | |
DE69828596T2 (en) | WAESSERIGE COMPOSITIONS CONTAINING A LIPIDIC AND A TENSID ON LANOLINBASIS AND ITS USE | |
DE4111982C2 (en) | Stable small particulate liposome preparations, their preparation and use | |
DE69912760T2 (en) | USE OF TOPICAL FORMULATIONS OF THE OIL-IN-WATER TYPE CONTAINING GALACTOLIPID MATERIAL AS AN EMULSION AGENT TO GIVE A LONG-LASTING EFFECT OF AN ACTIVE ACTIVE SUBSTANCE CONTAINING IT | |
EP2658610B1 (en) | Colloidal carrier system with penetration properties for encapsulating lipophilic active agents and oils for topical use | |
KR20130134532A (en) | Multilayer liquid crystal vesicle for relieving skin irritation and for recovering skin barrier, and cosmetic composition comprising the same | |
DE69112849T2 (en) | AQUEOUS PHOSPHOLIPID VESICLE DISPERSION, METHOD FOR THE PRODUCTION AND USE THEREOF. | |
WO2013023641A2 (en) | Method for producing a composition for application to the skin | |
EP3568123B1 (en) | Introduction of hardly soluble and/or watersoluble active agents with lipid based nanoparticles/nanovesicles into a hydrophilic threedimensional network of cellulose | |
US10596117B1 (en) | Lipoleosomes as carriers for aromatic amide anesthetic compounds | |
DE69713896T2 (en) | PHARMACEUTICAL FORMULATIONS FOR TOPICAL USE WITH VIT. E ACETATE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8122 | Nonbinding interest in granting licences declared | ||
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
8320 | Willingness to grant licences declared (paragraph 23) | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: LAUTENSCHLAEGER, HANS, DR., 42799 LEICHLINGEN, DE |